Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 642 of 5804
-
New pill combo aims to tackle tough leukemia
Disease control Recruiting nowThis is a multi-center open clinical study aimed at evaluating the efficacy and safety of Clifutinib Besylate combined with chemotherapy in newly-treated adult subjects with AML
Phase: PHASE1, PHASE2 • Sponsor: Sunshine Lake Pharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Army tests IV antiviral against Kidney-Damaging hemorrhagic fever
Disease control TerminatedMultisite protocol to provide IV Ribavirin treatment to patients with probable or suspected case of Hemorrhagic Fever with Renal Syndrome (HFRS)
Phase: PHASE2 • Sponsor: U.S. Army Medical Research and Development Command • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New pill shows promise for tough lung cancer
Disease control Recruiting nowThis is an open label phase I/phase II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, preliminary efficacy of Dositinib in participants of locally advanced or metastatic non-small cell lung cancer with positive EGFR mutation.
Phase: PHASE1, PHASE2 • Sponsor: Henan Genuine Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New pill could tame rare Muscle-Skin disease
Disease control OngoingThis is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of treatment with brepocitinib (TYK2/JAK1 inhibitor) in adults with dermatomyositis (DM). The primary objective of this study is to assess the efficacy of two dose levels of brepocitinib in compari…
Phase: PHASE3 • Sponsor: Priovant Therapeutics, Inc. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New drug offers hope for patients who Can't tolerate sunlight
Disease control CompletedThis is a Phase 2, multi-center, double-blind, placebo-controlled, parallel group study of bitopertin to evaluate the safety, tolerability, efficacy, and PPIX concentration change in participants with EPP. Participants may roll over to an open label extension portion after comple…
Phase: PHASE2 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Can a powerful drug cocktail halt multiple myeloma before it starts?
Disease control OngoingBackground: Multiple myeloma (MM) is a tumor in which malignant plasma cells accumulate in the bone marrow. It can cause organ damage and is not curable. Researchers want to see if a combination drug treatment can help. Objective: To try to prevent or slow down developing MM a…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Ayahuasca or esketamine: which eases depression better?
Symptom relief CompletedDouble-blind, randomized trial comparing 4 weekly doses of oral ayahuasca and esketamine in patients with major depression.
Phase: PHASE2 • Sponsor: University of Sao Paulo • Aim: Symptom relief
Last updated Jun 27, 2026 08:07 UTC
-
Brain zaps guided by scans: a new hope for untreatable depression?
Disease control Recruiting nowTreatment resistant depression remains a major problem for individuals and society. Surgical procedures may provide relief for some of these patients. The most frequently considered surgical approach is deep brain stimulation (DBS) of a part of the brain called the subcallosal ci…
Phase: NA • Sponsor: Nader Pouratian • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Heart attack patients get early drug to cut risk of another attack
Disease control OngoingThe primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic stroke, arterial revascularizat…
Phase: PHASE4 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Starting before pregnancy: new hope to stop childhood obesity
Prevention OngoingIntroduction: The prevalence of childhood overweight and obesity has risen from just 4% in 1975 to more than 18% in 2016. Little is known about adiposity of the infant, but it positively associates to the mother's BMI. Globally, the prevalence of overweight has tripled since 1975…
Phase: NA • Sponsor: Steno Diabetes Center Copenhagen • Aim: Prevention
Last updated Jun 27, 2026 12:08 UTC
-
Radiation beads plus immunotherapy: a new hope for advanced liver cancer?
Disease control Recruiting nowThis is a multi-national, phase II, parallel-arm, double-blind, placebo-controlled, two-arm study designed to assess the efficacy and safety of SIRT-Y90 followed by atezolizumab plus bevacizumab \[study arm\], versus SIRT-Y90 followed by placebo \[control arm\] in patients with l…
Phase: PHASE2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New hope for kids with tough cancers: GAIA-102 trial launches
Disease control Recruiting nowCohort A(GAIA-102 alone): Confirm the safety of GAIA-102 alone for refractory/relapse neuroblastoma or pediatric solid tumors with lung metastases, and decide recommended dose for Phase II. Cohort B(GAIA-102 with Dinutuximab): Confirm the safety of GAIA-102 with Dinutuximab, F…
Phase: PHASE1 • Sponsor: Kyushu University • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control OngoingThis is a first-in-human (FIH), Phase 1/2, open-label, multicenter study to assess safety and determine the recommended Phase 2 dose (RP2D) of BOXR1030 administration after lymphodepleting chemotherapy (LD chemotherapy) in subjects with glypican-3 positive (GPC3+) advanced solid …
Phase: PHASE1, PHASE2 • Sponsor: Sotio Biotech Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New drug cocktail shows promise for lung cancer patients
Disease control CompletedA Randomized, Double-blind, Controlled, Multi-center Phase 2 Clinical study to Investigate the Efficacy and Safety of Tucidinostat (Chidamide) Combined with Tislelizumab as First-line Treatment for PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Phase: PHASE2 • Sponsor: Chipscreen Biosciences, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Robots take on breast cancer surgery: a new trial tests safety and survival
Disease control Recruiting nowResearch Purpose The present study is designed to generate the strongest evidence available on the role of robotic surgical systems in breast cancer surgery and to elucidate the clinical value of immediate breast reconstruction (IBR) conducted in conjunction with robot-assisted n…
Phase: NA • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Promising chemo cocktail shows hope for AML patients under 60
Disease control CompletedThe goal of this clinical trial is to evaluate the response and safety of Cladribine plus Homoharringtonine and Cytarabine regimen (CHA) protocol in de novo acute myeloid leukemia with age \<60y. This is a prospective, single-armed mono-center based investigator-initiated trial. …
Phase: PHASE2 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New gout pill shows promise in lowering uric acid levels
Disease control CompletedThe aim of this 6-month randomized multi-regional double-blind parallel group placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
Phase: PHASE3 • Sponsor: LG Chem • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New pill shows promise for Hard-to-Treat blood cancers
Disease control OngoingThe purpose of this study is to evaluate the efficacy of BGB-11417 in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
Phase: PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New combo attack targets hard-to-treat KRAS G12C cancers
Disease control OngoingThis is Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G12C mutation.
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Brain tumor treatment showdown: should radiation come before or after surgery?
Disease control OngoingThis phase III trial compares the usual treatment of surgery after stereotactic radiosurgery (SRS) to receiving SRS before surgery in treating patients with cancer that has spread to the brain (brain metastases). Stereotactic radiosurgery is a type of radiation therapy that deliv…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC